When is VERA's next earnings date?

Based on SEC filing cadence, Vera Therapeutics Inc. (Class A) (VERA)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is VERA stock expected to move on earnings?

Volatility modeling currently projects a ±11.2% event move for VERA, spanning a range between $26.86 and $33.64.

Stock Ratings / Health Care / VERA / earnings

XNCR (47) AUPH (74) HRMY (86) PRGO (49) ⌘ Pro Terminal →

Vera Therapeutics Inc. (Class A) (VERA) Next Earnings Date & Expected ±11.2% Move

$30.25 -2.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $30.06

Vera Therapeutics Inc. (Class A) (VERA) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $2.23B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VERA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VERA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Vera Therapeutics Inc. (Class A) (NASDAQ: VERA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $30.25 (-2.36% 1D, market cap $2.23B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VERA ranks #750 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VERA compare to XNCR and AUPH in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VERA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XNCR (Xencor Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B) and AUPH (Aurinia Pharmaceuticals Inc) posts a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VERA?

▼

Per VERA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831828), Vera Therapeutics Inc. (Class A) generated $883.3M in revenue (+88.7% YoY), -$299.6M in net income, and -$241.7M in free cash flow against $734.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $30.07 (-0.61%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VERA)Realized 20D OHLCV Swing Band: ±11.2%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY VERA SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$26.79+12.2% Next Q

Q2 (-2Q)

Grade E$30.06-0.2% Next Q

Q3 (-1Q)

Grade E$29.99+0.9% Next Q

Current

Grade E$30.25-9.4% Hist 90D α

Trajectory: E (23) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VERA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VERA currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($31.91) and Max Pain ($31.76) forces dealer call-delta covering toward $58.85.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VERA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VERA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±11.2% Swing Band

±$3.39 Expected Swing

MODEL EARNINGS SETUP GAUGE

VERA Quantitative Pre-Earnings Setup: 31/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (31/100)Model Risk Weight (69/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$883.3M	-$299.6M	-$241.7M	52%
FY 2024	2024-12-31	$468.1M	-$152.1M	-$135.7M	52%
FY 2023	2023-12-31	$285.6M	-$96.0M	-$92.2M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VERA)

✓Walkthrough of VERA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VERA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.81%▼ DESCENDING CHANNEL

2026-11-03O $30.53H $30.98L $30.25C $30.25VOL 1.08M

RES: $32.04SUP: $25.57SMA50: $31.91SMA200: $36.80

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VERA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VERA Butterfly Map → + Track VERA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VERA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VERA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VERA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VERA)

Health Care Rank #750 of 1016 ⚔️ XNCR vs VERA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VERA vs. XNCR, AUPH, HRMY, PRGO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vera Therapeutics Inc. (Class A) (VERA) ranks #750 by composite RQD confidence (31/100, grade E) and #238 by equity capitalization ($2.23B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with VERA at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VERA ACTIVE Vera Therapeutics Inc. (Class A)	E	31/100	—	—	-35.0%	-2.36%	$2.23B	Benchmark Subject
XNCR Xencor Inc.	D	47/100	—	—	-21.3%	-0.54%	$2.22B	/xncr-vs-vera →
AUPH Aurinia Pharmaceuticals Inc	B	74/100	8.0x	88.5%	16.5%	-3.06%	$2.22B	/auph-vs-vera →
HRMY Harmony Biosciences Holdings Inc.	A	86/100	14.2x	77.2%	63.0%	-2.19%	$2.26B	/hrmy-vs-vera →
PRGO Perrigo Company plc	D	49/100	—	35.1%	-13.6%	-0.19%	$2.19B	/prgo-vs-vera →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001831828

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vera Therapeutics Inc. (Class A) (VERA) reported GAAP revenue of $883.3M (+88.7% vs. FY2024 revenue of $468.1M , and +209.3% cumulative change since FY2023) , GAAP net income of -$299.6M, operating cash flow of -$241.1M, and free cash flow of -$241.7M (-78.2% YoY). On the balance sheet, VERA closed FY2025 with $734.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$883.3M	-$299.6M	-$241.1M	-$241.7M	$734.7M	—
FY2024 (FY)	2024-12-31	$468.1M	-$152.1M	-$134.7M	-$135.7M	$655.7M	—
FY2023 (FY)	2023-12-31	$285.6M	-$96.0M	-$92.2M	-$92.2M	—	—

3. VERA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VERA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VERA compare to XNCR and AUPH in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VERA?

Where is VERA trading relative to its 50-day, 200-day, and 52-week technical levels?

VERA last traded at $30.25 (-2.36% on volume of 2,111,205 shares), positioning the stock -5.20% below its 50-day simple moving average ($31.91) and -17.80% below its 200-day simple moving average ($36.80). Across its 52-week range of $23.05 to $56.05, VERA sits at the 21.8% percentile with a 14-day RSI of 52.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($26.86 to $33.64).

Direct Sub-Reports: VERA RQD Cockpit VERA 12M Forecast VERA Earnings & Move VERA Dividends & DRIP VERA Insiders & 13F VERA Whale Options VERA Profit Sankey VERA News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

VERA — Vera Therapeutics Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:26:24Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

VERA scores 32 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 7 / 20. The rating cites ROIC of -35% and an FCF yield of -10.99%. For a prospective investor, this indicates the business is currently consuming cash rather than generating it relative to its capital base.
**Whale 13F Flow: 6 / 20.
Insider Conviction: 3 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow. This is the lowest-scoring pillar after Fundamental Cash Engine, and it points to weak insider-side conviction in the data provided.
Macro Regime Fit: 6 / 20. The rating cites a Beta of 1.0 and sector sensitivity, indicating market-level volatility exposure without a clear defensive offset in the source data.
Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and Debt/Equity of 0.5. The F-Score of 2/9 is a weak reading on the Piotroski scale and is a primary reason this pillar scores as it does.

Taken together, the rating frames VERA as a forensic-risk name: losses, negative cash flow, and a weak F-Score dominate the picture, with institutional and market-sensitivity signals providing limited offset. Upside drivers the data supports are the recent positive news flow and institutional interest; the valuation tradeoff is that a $2.2B market capitalization is being carried against negative ROIC and negative free cash flow, with no earnings per share or P/E figure in the source data to anchor valuation. The overall stance is avoid.

2. Business Model, Unit Margins & SEC Financial Trajectory

Vera Therapeutics Inc. (Class A) (VERA) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations..2B. Revenue is reported as — across the available periods.

Reported revenue is — in each period, and operating and net losses widened from FY 2023 through FY 2025. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Cash rose from $92.6M in FY 2024 to $354.7M in FY 2025, while Debt/Equity is 0.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Positive FDA approval and Phase III IgA nephropathy results, with Raymond James reiterating a Strong Buy, support the near-term catalyst narrative. With Fundamental Cash Engine at 7/20 (ROIC -35.0%, FCF yield -10.99%) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $23.05 – $56.05 52-week range.
🐻 Primary Bear Case: Negative ROIC of -35%, free cash flow of -$241.7M in FY 2025, and an F-Score of 2/9 sit against a $2.2B market capitalization. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VERA carries a macro regime beta of 1.00 and gross margin of —.

Key Question #1: What is the current analyst consensus and price target coverage, given the analyst data is absent?
Key Question #2: What is the cash runway implied by the FY 2025 cash balance of $354.7M against the -$241.7M free cash flow?
Key Question #3: How sensitive is VERA's — gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?

VERA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vera Therapeutics Inc. (Class A) (VERA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VERA Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 20h ago

Do Vera Therapeutics' (VERA) High-Profile IgAN Data Show Durable Moat or Crowded Mechanism Risk?

Yahoo Finance report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stocktwits • 23h ago

VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics

Stocktwits report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Raymond James reiterates Vera Therapeutics stock Strong Buy on kidney disease data

Investing.com report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Vera Therapeutics (Nasdaq:VERA) - Stock Analysis

Simply Wall St report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Vera Therapeutics, Inc. Estimates – NASDAQ:VERA

TradingView report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results

Yahoo Finance report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Vera Therapeutics (VERA) Short Interest & Short Float | Updated Oct 2026

MarketBeat report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Vera Therapeutics leaders will speak in Boston and meet investors.

Stock Titan report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VERA Bull vs. Bear Conversation Board — What's Your Call at $30.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VERA 🐻 33% BEARISH CONVICTION

BR BreakoutHunter Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $40.89 (+32.0%)

📌 Pinned Debate

Positive FDA approval and Phase III IgA nephropathy results, with Raymond James reiterating a Strong Buy, support the near-term catalys

Long VERA at $30.98 targeting $40.89. Positive FDA approval and Phase III IgA nephropathy results, with Raymond James reiterating a Strong Buy, support the near-term catalyst narrative.. Institutional whale score is 6/20 and the risk/reward vs. the $23.05 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@BreakoutHunter Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $30.98 and keeping dry powder in case we test $28.81.

MU MultipleCompression Valuation Discipline 🐻 BEARISH 🎯 Target: $26.02 (-16.0%)

Spot @ $30.98

Negative ROIC of -35%, free cash flow of -$241.7M in FY 2025, and an F-Score of 2/9 sit against a $2.2B market capitalization.

I respect the product at Vera Therapeutics Inc. (Class A), but the stock at $30.98 is a different story. Negative ROIC of -35%, free cash flow of -$241.7M in FY 2025, and an F-Score of 2/9 sit against a $2.2B market capitalization.. FCF yield is -10.99% and RQD sits at 31/100 (E) — why pay up here when you can wait for next quarter's numbers?